INTRODUCTION
Influenza outbreaks occur every year because influenza viruses change their antigenic properties (i.e., the envelope glycoproteins: hemagglutinin, abbreviated "H" and neuraminidase, abbreviated "N") very frequently. Major changes in hemagglutinin and neuraminidase are called "antigenic shifts," while minor changes in these envelope glycoproteins are referred to as "antigenic drifts." Antigenic shifts lead to epidemics and pandemics of influenza A. [1] Three major subtypes of hemagglutinins (H1, H2, and H3) and 2 subtypes of neuraminidases (N1 and N2) have been described in influenza A viruses that are pathogenic for humans. Influenza B viruses have antigenic drifts in the hemagglutinin glycoprotein. In late March 2009 and early April 2009, an epidemic of patients with H1N1 influenza A virus infection was detected. [2, 3] The H1N1 strain involved in that epidemic emerged after a genetic mutation of influenza viruses in pigs (swine influenza), birds (avian influenza), and humans. In June 2009, the World Health Organization (WHO) announced a global pandemic, the highest stage of their classification system. [4] The pandemic was not declared to have ended until August 2010. [5] It had a high morbidity and mortality rate among children and young adults worldwide. [6] Although most of the reported mortality was observed in patients with various underlying chronic illnesses, one-third of the hospitalized patients with severe influenza had no concomitant diseases and were otherwise healthy. [7] When compared with the general population, the mortality rate of pregnant women with H1N1 influenza A was higher. [8, 9] Obesity was also determined to be an independent risk factor for severe influenza. [10] The Centers for Disease Control and Prevention (CDC) in the United States of America (USA) reports influenza activity regularly by following up influenza virus isolates worldwide in collaboration with the WHO. During the influenza season, surveillance data is updated weekly on the website of CDC. [11] Moreover, "FluNet," a global influenza virus surveillance database is available on the website of the WHO. [12] According to the data reported on these reference sites (as shown in the graph obtained from the WHO website in Fig.  1 nd week of 2015. The subtyping revealed that the majority of the influenza viruses isolated were H1N1 and H3N2. As reported by the WHO, the first laboratory-confirmed case of influenza in the European region was detected in the 40th week of 2015. The sub-typing of influenza viruses isolated in European countries was reported to be an influenza A (H1N1) virus in the majority of cases, followed by an influenza B virus. Given that knowledge, the aim of this study was to determine the etiological profile, clinical course, and outcome of the patients hospitalized with severe influenza/SARI in a tertiary medical center during the 2015-2016 influenza season.
MATERIAL AND METHODS
A retrospective descriptive case series study was performed. Patients with severe influenza who were admitted to the emergency department of the hospital between December 1, 2015 and April 15, 2016 and who required hospital admission were included in the study. Patient management was established according to the Turkish Ministry of Health (TMH) recommendations. Any patient with a fever >38°C (axillary measurement and the cause of the fever cannot be explained by any other reason) and with at least 1 of the following symptoms: i) myalgia, ii) sore throat, iii) headache, iv) nasal discharge, or v) cough and dyspnea was regarded as a "possible influenza case." The inclusion criteria for children with influenza-like illnesses were at least 1 of the following: i) temperature ≥37.8°C, ii) headache, iii) myalgia, iv) malaise, and at least 1 of the following: i) cough, ii) sore throat, or iii) shortness of breath, and hospital admission within 7 days of the appearance of clinical conditions, according to European Centre for Disease Prevention and Control (ECDC) definition. [13] If there is any indication for hospitalization or any increased risk of morbidity and mortality due to influenza (as listed below), a possible influenza case is admitted to Indications for admission to the intensive care unit (ICU) include:
• Unresolved hypoxia resistant to therapy, progressive hypercapnia, • Hemodynamic disturbances, and • Sepsis and septic shock.
Patients with an increased risk of morbidity and mortality due to influenza include: The presence of dyspnea, tachypnea, tachycardia, hypotension, hypoxia, mental status changes, severe dehydration, or a chest X-ray compatible with bronchopneumonia/pneumonia was considered "severe influenza." Nasopharyngeal swab/aspirate specimens were obtained from all hospitalized patients and tested for respiratory viruses using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. The diagnostic test of molecular typing was performed by the Istanbul Public Health Laboratory in the context of a SARI surveillance study. The inclusion criteria were:
• Reference to the emergency department, or the outpatient polyclinics of ınfectious diseases, pediatrics, pulmonary medicine, or family medicine with the initial diagnosis of influenza during the 2015-2016 influenza season, • Management according to the ınfluenza case management algorithm developed by the TMH (Fig. 2 ), • Hospitalization because of severe influenza and, • Provision of a specimen of nasopharyngeal aspirate for diagnosis.
Patients with an initial diagnosis other than influenza/ influenza-like illnesses or SARI and those who were not admitted to the hospital for inpatient management were excluded from the study.
The primary endpoints were exclusion of influenza diagnosis by negative PCR test results, mortality, and discharge from hospital. All of the patients hospitalized with the initial diagnosis of severe influenza were administered oral oseltamivir therapy as soon as possible after nasopharyngeal aspirate specimens had been obtained (In adults: 75 mg 2 times daily for 5 days; in children: the dose and duration of oseltamivir was determined by the pediatricians according to the guideline recommendations).
RESULTS
Nasopharyngeal aspirate samples of a total of 95 hospitalized patients were tested. 
DISCUSSION
During an outbreak, the diagnosis of influenza can be made clinically. Adults with mild disease who are younger than 65 years of age and who have no high-risk factors usually do not require laboratory testing or treatment. [14] In hospitalized patients with SARI, laboratory testing (e.g., RT-PCR) is necessary for an accurate diagnosis in order to establish specific treatment. The Infectious Diseases Society of America (IDSA) published guidelines on the diagnosis and management of influenza in 2009. [15] The CDC has also published documents on the diagnosis of influenza. [16] We obtained nasopharyngeal swabs for influenza testing. Although nasopharyngeal aspirates or washings have been reported to be more sensitive than nasopharyngeal swabs, [17] the clinicians in our study preferred swabs, since they are easier to obtain. Nearly one-third of the specimens were negative for any respiratory virus. If we had 
DEFINITIVE CASE
• Continue the therapy
THINGS TO DO AFTER HOSPITALISATION
• In addition to standard infection control measures, droplet isolation precautions are also applied.
• Appropriate specimens are obtained.
• If more than one patient in a room are to be hospitalised, at least one meter distance is spared between them.
INDICATIONS FOR INTENSIVE CARE
• Refractory hypoxemia, • Progressive hypercapnia • Hemodynamic disturbance • Signs of sepsis and shock
PROBABLE CASE (consistent with clinical definition)
• Patients requiring hospitalisation because of severe clinical condition are hospitalised and antiviral treatment is started. Specimens are obtained from hospitalised patients.
• Other patients who do not require hospitalisation but are in the risk group are given antiviral therapy.
• Avoidance of contact with other people is recommended until the sighn resolve.
Dyspnea or respiratory distress
• Change in vital signs: In adults; arterial hypotension (systolic blood pressure <90 mmHg and diastolic BP <60 mmHg), decrease of >40 mmHg in BP, in children; capillary refill >2 min. Increase in respiratory rate (>30/min in adults, more than reference values according to age in children), increase in heart beat (>120/min), more than reference values according to age in children) • Hypoxia, oxygen saturation ≤92% by pulse oxymetry • Change in mental situation; newly-emerging confusion, agitation or seizure • Severe dehydration (weak peripheral pulse, decrease in skin turgor, undetectable blood pressure, loss of 10% of total body weight defined by sunk eyes, in children; inability to take oral liquids, severe or persistent vomiting, inability to urinate or decrease in eyedrops during crying) • Presence of bronchopneumonia or pneumonia on chest X-ray YES Negative Positive INFLUENZA CASE MANAGEMENT ALGORITHM been able to get nasopharyngeal aspirates or washings, the positivity rate might have been higher. Tanriover et al. [18] reported a rate of 18.4% influenza-positive, with an H1N1 strain predominance in their study, which involved patients in 5 tertiary care hospitals during the 2015-2016 influenza season in Turkey. In our study, more than half of the patients were adults and more than half were female. The mean age of the children hospitalized with SARI was 2 years, and more than half of them were also female.
Influenza with fever, headache, myalgia, nonproductive cough, sore throat, and nasal discharge is referred to as "uncomplicated influenza." [19] We use the term "severe influenza" or "complicated influenza" for patients having any indications for hospitalization or any complications of influenza (e.g., pneumonia, which is the most common complication, or muscle and/or central nervous system complications). Only patients hospitalized with a presumptive diagnosis of severe influenza were included in this study.
We detected different etiological viruses in this influenza season. Two or 3 different influenza strains may circulate concurrently in an influenza season. [11] The most common etiological agent (nearly 65%) was the H1N1 influenza A virus, followed by the H3N2 influenza A virus. Different influenza viruses may cause diseases of different severity. In one study, no significant differences were reported between influenza A and B infections among ≥65-year-old hospitalized adults regarding median length of stay in the hospital, admission to the ICU, or mortality. [20] The most severe disease was caused by the H3N2 subtype of the influenza A virus, followed by influenza B viruses. The H1N1 influenza A virus caused milder disease. [21] However, the pandemic H1N1 influenza A caused more severe disease than H3N2 influenza A or influenza B in hospitalized patients during the 2010-2011 influenza season. [22] Sporadic cases of other respiratory viruses have also been observed, although fewer in number than influenza viruses. In a review of upper respiratory infections in older adults that included 497 episodes in total from the influenza season of 1992-1994, the etiological pathogen was identified in 43% of the patients. [23] Influenza A or B viruses accounted for only 10%. The most common pathogens were rhinoviruses (more than half), followed by coronaviruses (one-fourth).
Among respiratory viruses, coronavirus causes approximately 5% to 10% of severe, community-acquired, upper respiratory tract infections in adults. Coronavirus infection occurs sporadically or in outbreaks. No specific treatment is recommended for coronavirus infections, aside from supportive care. [24] Six cases of coronavirus infection were detected in our study. RSV also causes acute respiratory tract illness in the form of seasonal outbreaks, like influenza viruses, during winter. [25, 26] It affects patients of all ages, but most commonly children younger than 1 year of age. [27] It is usually self-limited, but it can cause severe infection in high-risk patients. Parainfluenza virus (PIV), metapneumovirus, influenza virus, rhinovirus, coronavirus, bocavirus, and adenovirus should be considered in the differential diagnosis of RSV. We detected 3 cases of concomitant RSV infection along with other respiratory viruses. HMPV was discovered in 2001. [28] It is a paramyxovirus that causes self-limited upper and lower respiratory tract infections in patients of all ages. Symptomatic disease most often occurs in young children or older adults. Patients with severe pneumonia and acute respiratory distress syndrome require hospitalization. At present, no specific antiviral therapy is available. [29] In our study, 1 child patient had concomitant coronavirus, HMPV, and RSV coinfection, and 2 adults had HMPV infection. HBoV was isolated in 2005. It is a parvovirus that is found in both respiratory and stool samples of children of 6 to 24 months of age with SARI. [30] It is frequently detected in children with respiratory disease in combination with other viruses or bacteria. In our study, 1 case of concomitant coronavirus and HBoV co-infection was observed. Moesker et al. [31] reported that they found 178 and 366 cases of HBoV and RSV, respectively, in their study of 990 patients who tested positive for a respiratory virus with RT-PCR. Forty-nine (28%) HBoV-positive patients and 72 (20%) RSV-positive patients were admitted to the ICU. PIVs cause mild upper respiratory tract infections in adults and children. [32] In immunocompetent adults, they usually cause asymptomatic or self-limited upper respiratory tract infections. However, in immunocompromised and older patients, they can cause life-threatening lower respiratory tract infections. At present, no specific antiviral drug is available for the treatment of severe cases. [33] Between 1990 and 2004, more than 40,000 cases of PIV were detected in a surveillance study that included children and adults in the USA. Among the serotypes, PIV-3 was the most common (in more than half of the patients). Only 2% PIV-4 was detected. [34] Rhinovirus is a member of the picornavirus family. It is one of the most common causes of the self-limited diseases called "the common cold." The major reservoir for rhinovirus is children. Only symptomatic treatment is recommended for infected patients. [35] Pregnant women with influenza usually have an increased risk of developing serious complications. They may require hospitalization and ICU admission more frequently than non-pregnant women with influenza. The mortality rate may also be higher in this patient group; therefore, prompt antiviral treatment is recommended for pregnant patients with confirmed or suspected influenza, even up to 2 weeks into the postpartum period. Early treatment within 2 days of symptom onset has been associated with a more favorable clinical course and outcome. However, beginning treatment >2 days after symptom onset in patients not yet improving can be beneficial. [8, 36] In our study, 6 (9%) patients were pregnant. Empirical oseltamivir treatment had been initiated within 2 days of symptom onset in 5 of them. Three had an influenza A infection. Only 1 pregnant patient who was brought to the emergency service late in the course of the disease required ICU follow-up, and unfortunately, she died due to complicated H1N1 influenza.
Young children with or without underlying diseases are at increased risk for hospitalization due to severe/complicated influenza. The classic symptoms of influenza may be absent in children. Complications of influenza, such as secondary bacterial infection (bacteremia, pneumonia, otitis media) and exacerbation of asthma may occur more frequently in this age group. [14] Fortunately, all of the children in our study who were hospitalized with the diagnosis of influenza/influenza-like illness (SARI) survived.
Oseltamivir, zanamivir, and peramivir are the neuraminidase inhibitors that are active against both influenza A and B viruses. At that time, only oseltamivir was available in our country. Patients benefit most from antiviral therapy when it is initiated within the first 48 hours of disease. Therefore, treatment should be initiated as soon as possible. Neuraminidase inhibitors have been reported to shorten the duration of influenza symptoms by 1 to 3 days if administered within the first 24 to 48 hours. [37] Oseltamivir and zanamivir are among the drugs classified in Pregnancy Category C. No adverse events caused by oseltamivir or zanamivir have occurred in pregnant women or their infants, but the available data are limited. [38] Only fifteen (one-fifth) of the patients with severe influenza required follow-up in the ICU. Among the ICU patients, a total of 9 adults died. Winterbauer et al. [39] reported that only 5 patients of 11 with severe influenza viral pneumonia survived after prolonged therapy in the ICU. In a study conducted in Turkey, half of the patients over 65 years of age were admitted to the ICU and one-third of them required mechanical ventilation. One-fourth died in the hospital. [18] In our study, the case-fatality rate of H1N1 infection among hospitalized patients was 14%.
In conclusion, two-thirds of the patients who were admitted to the hospital had an influenza A-H1N1 infection. Seven (16.7%) of them required ICU follow-up. The H1N1 case-fatality rate was 14.3%. Patients with risk factors who have severe influenza should be hospitalized. Oseltamivir treatment should be given early in the course to prevent mortality. Patients at risk for influenza should be vaccinated, and hospitals and medical staff should be prepared for the next influenza season.
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